Cargando…
Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug‐Induced Liver Injury
Tolcapone and entacapone are catechol‐O‐methyltransferase (COMT) inhibitors developed as adjunct therapies for treating Parkinson's disease. While both drugs have been shown to cause mitochondrial dysfunction and inhibition of the bile salt export protein (BSEP), liver injury has only been asso...
Autores principales: | Longo, DM, Yang, Y, Watkins, PB, Howell, BA, Siler, SQ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728295/ https://www.ncbi.nlm.nih.gov/pubmed/26844013 http://dx.doi.org/10.1002/psp4.12053 |
Ejemplares similares
-
Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters
por: Yang, K, et al.
Publicado: (2017) -
Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials
por: Longo, DM, et al.
Publicado: (2017) -
Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym
por: Longo, Diane M, et al.
Publicado: (2020) -
Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses
por: Shoda, Lisl KM, et al.
Publicado: (2017) -
Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury
por: Woodhead, Jeffrey L., et al.
Publicado: (2014)